Season's Greetings

We support the Swedish cancer society

Active Biotech Interim report January – September 2019

PRESS RELEASE

New preclinical data on naptumomab estafenatox will be presented at the Society for Immunotherapy of Cancer’s 34th Annual Meeting

POSTER

Active Biotech and NeoTX today announce first patient dosed in the Phase 1b trial of naptumomab estafenatox in combination with durvalumab in solid tumors

PRESS RELEASE

Active Biotech's partner NeoTX enters clinical collaboration with AstraZeneca to evaluate ANYARA in combination with IMFINZI® (durvalumab) in the upcoming Phase 1b/2 study

PRESS RELEASE

ANYARA Tumor Targeting Immunotherapy

ANYARA: Clinical Development

Develops Novel Treatments for Cancer and Neurodegenerative Diseases

ABOUT US

An Experienced Team — Building Solid Partnerships

MANAGEMENT

Neurodegeneration & Inflammation

Effective treatments of diseases with high medical need

Active Biotech focuses on the research and development of pharmaceuticals in therapeutic areas with high medical need, in which the immune system is of central importance. The project portfolio comprises small, orally active immunomodulatory molecules and antibody-based immunotherapy being developed for the treatment of cancer, as well as neurodegenerative diseases and inflammation.

Diseases where the immune system is of central importance